Shanghai Junshi Bioscience Co., Ltd.

This Phase II trial tests two experimental drugs, JS212 and JS213, alone or together, in 410 adults with advanced solid tumors (kidney, prostate, bladder, or skin cancer). The main goal is to see if the drugs shrink tumors. Researchers will also check safety and how long any bene…

This study tests a new drug called JS207, a bispecific antibody that targets PD-1 and VEGF, in combination with chemotherapy or another experimental drug (JS212) for people with advanced non-small cell lung cancer that has specific gene mutations. The participants have already tr…

This study tests a combination of four drugs (JS212, JS207, Toripalimab, and JS213) in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will receive the drugs by …

This study tests a new drug called JS212, which is designed to target two proteins on cancer cells (EGFR and HER3) and deliver a chemotherapy-like payload directly to them. It is being tested in combination with other standard cancer drugs in 80 adults with metastatic colorectal …

This study tests a combination of three drugs (JS212, JS001, and 5-FU) in 280 people with advanced esophageal squamous cell carcinoma that cannot be cured by surgery. The goal is to see if the combo is safe and can shrink tumors or slow the disease. Participants must not have had…

This Phase 2 trial tests two different drug combinations—JS207 plus 9MW2821 or JS207 plus albumin paclitaxel—as a first treatment for people with recurrent or metastatic triple-negative breast cancer. The study will enroll 80 participants to see if these combinations can shrink t…

This study tests a new drug called JS207, which targets both PD-1 and VEGF, in people with advanced non-small cell lung cancer that got worse after standard chemotherapy and immunotherapy. About 66 participants will receive JS207 alone or combined with another drug (JS004 or doce…

This Phase 3 trial is testing an experimental drug called JS107 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least one prior therapy. The study will enroll about 560 participants who have a specifi…